Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,001–1,100 of 3,116
Nicholls, S. J., Ryan, D. H., Deanfield, J. E., Ferreira, D., Lang, C. C., Lincoff, A. M., Lingvay, I., Lübker, C., Terns, P. P., Rasmussen, S. M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.4824 · Cited by 10
Self-citationLiu, L., Zheng, Y., Luo, K., Ma, H., Jiang, W., Luo, R., Pan, C., He, T., Ren, H., Tse, G., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322702 · Cited by 9
Nguyen, X.-M. T., Li, Y., Czernichow, S., Rassy, N., Houghton, S. C., Lu, B., Ho, Y.-L., CHAREST, B. R., Wang, D. D., GAGNON, D. R., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00395-x · Cited by 6
Pharmacologic Therapies for Type 2 Diabetes
Kuo, B., & Li, J. H. (2025) · NEJM Evidence · doi:10.1056/evidra2400265 · Cited by 9
Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities
Evans, P. C., Vilahur, G., Kleinbongard, P., Osto, E., Remme, C. A., Madonna, R., Aksentijević, D., Sourij, H., Davidson, S. M., Santovito, D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag116 · Cited by 10
Tang, W. L., Beyene, T. J., Tang, W., Heidenreich, P. A., Asch, S., & Yong, C. M. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1016/s0735-1097(24)03691-x · Cited by 7
Cordova, F., & Malaga, N. C. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.11.024 · Cited by 9
Peterson, A. L. H., Ashraf, A. P., Bachman, J., Hegele, R. A., Rashad, M., South, A. M., Tran, A. H., Zachariah, J. P. V., & Wong, J. P. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000195 · Cited by 8
Virani, S., Zieroth, S. R., Aleksova, N., Anderson, K., Clarke, B., Ducharme, A., Ezekowitz, J. A., Foroutan, F., Giannetti, N., Jain, R., et al. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.027 · Cited by 34
RetractedChang, Y., Peng, C.-Y., Chi, K., Song, J., Chang, Y., Chiang, C.-H., Gao, W., & Chiang, C. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf017 · Cited by 7
Ahn, H. M., Kaelber, D. C., Hoell, N. G., Ambani, R. N., Quatromoni, J. G., Khalifeh, A., Kirksey, L., Hanak, C. R., Cameron, S. J., Lyden, S. P., et al. (2025) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2025.11.021 · Cited by 11
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Cesaro, A., Acerbo, V., Longo, M., Antonucci, A., Maiorino, M. I., Monaco, M. G., Martelli, E., Giudice, G., Esposito, K., Giorgino, F., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag077 · Cited by 11
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?
Lah, S., & HOCKING, S. L. (2025) · Internal Medicine Journal · doi:10.1111/imj.16625 · Cited by 8
The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
Guo, Y., Chu, L., Cai, X., Wu, H., Yan, J., Li, Z., Jiao, R., Bai, S., Yang, W., Lv, F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110867 · Cited by 6
Edwards, M., Thomas, M., FARR, M. A., et al. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100114 · Cited by 6
The Combined Effect of Smoking and Obesity on Hypertension: Implications for Clinical Management
Aragiannis, D., Kasiakogias, A., Iliakis, P., Sagris, Μ., Tatakis, F. P., Manta, E., Andrikou, I., Konstantinidis, D., & Tsioufis, K. P. (2025) · Current Hypertension Reviews · doi:10.2174/0115734021351026250126165154 · Cited by 8
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Sundararaman, L. V., Gouda, D., Kumar, A., Sundararaman, S., & Goudra, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061978 · Cited by 7
2026 ESC Guidelines on cardiac rehabilitation
Bäck, M., Wilhelm, M., Marcin, T., Machado, F. V. C., Sandberg, A., Buccheri, S., Conde, A. C., Czapla, M., Rosa, S. D., Gibson, I., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag099 · Cited by 41
Sebhat, I. K., Murphy, M. J. M., Zheng, S., Lovelett, R. J., Engelstoft, M. S., Kosinski, D., Yang, X., Dunn, V., Whang, J., Lombardo, M., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.001 · Cited by 9
Innovations in Diagnosis and Treatment of Coronary Artery Disease
Agamy, S., Zaghloul, S., Khan, Z. U., Shahin, A., Kishk, R., Smman, A., & Candilio, L. (2025) · Diagnostics · doi:10.3390/diagnostics16010098 · Cited by 13
“The SELECT trial showed semaglutide lowered MACEs by 20% in overweight/obese individuals with established CVD but without diabetes, high-lighting glucose-independent heart protection [92].”
Devadoss, R., Dhillon, G. S., Sharma, P., Verma, R. K., Munjal, R. S., & Kashyap, R. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11010015 · Cited by 10
Glucagon-like peptide-1 receptor agonists and aspiration risk
McIsaac, D. I., & Bryson, G. L. (2024) · BMJ · doi:10.1136/bmj.q1986 · Cited by 8
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
“14 There is also growing interest in the use of GLP-1 RAs for heart failure with preserved ejection fraction 15,16 given their effects on weight, inflammation, and hemodynamics.”
Prediabetes and diabetes mellitus type II after ischemic stroke
Moelgg, K., Karisik, A., Scherer, L., Buergi, L., Dejakum, B., Komarek, S., Granna, J., Boehme, C., Pechlaner, R., Toell, T., et al. (2025) · European Stroke Journal · doi:10.1177/23969873241304301 · Cited by 6
Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf779 · Cited by 6
“3,46 In the Swedish Obesity Study, bariatric surgery was shown to reduce body weight by 16% (corresponding to an average reduction from 42.4 to 35.6 kg/m 2 in BMI) and the risk of cardiovascular events by 33% after 15 years of follow-up.”
InfluentialAcute Coronary Syndromes: State-of-the-Art Diagnosis, Management, and Secondary Prevention
Yuan, X., Nienaber, S., Akin, I., Kabir, T., & Nienaber, C. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010016 · Cited by 11
Ard, J. D., Kaplan, L. M., Kahan, S. I., Kumar, R. B., Kan, H., Dunn, J. P., Sims, T. J., Ahmad, N. N., King-Concialdi, K., Drakeley, S. C., et al. (2025) · Population Health Management · doi:10.1089/pop.2024.0239 · Cited by 10
Li, H.-Y., Chan, T.-K., Shih, K. C., Cheung, B. M. Y., Yiu, K.-H., Tse, H.-F., & Chan, Y. (2026) · Diabetes Care · doi:10.2337/dc25-1929 · Cited by 12
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
Heart Failure With Mildly Reduced Ejection Fraction
Wu, L., Rizwan, A. M., Rodriguez, M., Hachem, K. E., Virk, H. U. H., Khawaja, M., Strauß, M., & Krittanawong, C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102476 · Cited by 13
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. L. T. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf004 · Cited by 9
Carey, I. M., Harris, T. J., Chaudhry, U. A. R., DeWilde, S., Limb, E. S., Bowen, L., Audi, S., Cook, D. G., Whincup, P. H., Sattar, N. A., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01828-z · Cited by 8
Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
Khan, M. S., Dawood, M. H., Handelsman, Y., Anker, S. D., Coats, A. J. S., Green, J. B., & Butler, J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag201 · Cited by 9
Tanashat, M., Al‐Ajlouni, Y. A., Abuelazm, M., Altobaishat, O., Manasrah, A., Turkmani, M. M., Khan, U., & Abouzid, M. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00726-z · Cited by 9
Heart failure with preserved ejection fraction therapeutics: in search of the pillars
Rafei, A. E., Harrington, J., Tavares, C. A. M., Guimarães, P. O., Ambrosy, A. P., Bonaca, M. P., Sauer, A. J., Vardeny, O., & Canonico, M. E. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10524-z · Cited by 8
Wilkinson, M., Rollin, T., Kuriakose, M., Haggerty-Goede, R. A. L., Miller, D. M., & Dunham‐Snary, K. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110370 · Cited by 6
Beck, J., Hasenböhler, F., Werlen, L., Lengsfeld, S., Meienberg, A., Bathelt, C., Vogt, D., Christ‐Crain, M., Burkard, T., & Winzeler, B. F. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf055 · Cited by 6
Harrington, J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10410-0 · Cited by 6
Bhargava, S., Rao, Z., Vanholder, R. C., Tacke, F., Noels, H., Jankowski, V., Hermann, J., & Jankowski, J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102295 · Cited by 9
“…indirectly enhances post-ischemic myocardial recovery by increasing nitric oxide production and GLUT-1 translocation and improves left ventricular contractility and mitochondrial respiratory capacity after infarction [100], with beneficial cardiovascular effects even in non-diabetic patients [101].”
Bays, H. E., Bloedon, L. T., Brennan, D. M., Lei, L., Lincoff, A. M., Nicholls, S. J., Plutzky, J., Powell, H. A., & Nissen, S. E. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037898 · Cited by 13
Self-citationSequence variants associated with BMI affect disease risk through BMI itself
Einarsson, G., Þorleifsson, G., Steinthórsdóttir, V., Zink, F., Helgason, H., Ólafsdóttir, Þ., Rögnvaldsson, S., Tragante, V., Ulfarsson, M. O., Sveinbjörnsson, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53568-9 · Cited by 7
Multiplicity Control in Clinical Trials
Lalonde, A., & Nissen, S. E. (2025) · NEJM Evidence · doi:10.1056/evidctw2400393 · Cited by 9
Dhivagaran, T., Butt, F. R., Arunasalam, L., Bae, I., Mikhail, D., Tao, B. K.-L., Xie, J. S., Balas, M., Popovic, M. M., & Margolin, E. (2026) · Neurology · doi:10.1212/wnl.0000000000214864 · Cited by 10
Schmucker, J., Kerniss, H., Hanses, U., Rühle, S., Marín, L. A. M., Osteresch, R., Fach, A., Eitel, I., Hambrecht, R., & Wienbergen, H. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf411 · Cited by 7
Myette, R. L., Lamarche, C., Odutayo, A., Verdin, N., & Canney, M. (2024) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581241232472 · Cited by 10
Damen, J. A., Idema, D. L., Vernooij, R. W. M., Veld, L. F. H. I. ’., Kusters, M. P. T., Lokerse, M. E., de Kanter, E., Spijker, R., van der Braak, K., Jenniskens, K., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-24-03764 · Cited by 9
Changing the paradigm in heart failure: shifting from treatment to prevention
Chang, A. J., Liang, Y., Girouard, M. P., Bhatt, A. S., Sandhu, A. T., Sauer, A. J., Greene, S. J., Harrington, J., Go, A. S., & Ambrosy, A. P. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10454-2 · Cited by 9
Chaitoff, A. M., Bendicksen, L., Feldman, W. B., Zheutlin, A. R., & Lalani, H. S. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-00308 · Cited by 6
Natali, L. D., de Oliveira, L. G. M. S., Barbosa, I. C. D. Q., & Portilho, N. D. P. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.07.009 · Cited by 7
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials
Savage, P., Cox, B., Shahmohammadi, M., Kelly, B. P., & Menown, I. B. A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02877-y · Cited by 9
Kowalska, M. K., El‐Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041886 · Cited by 10
GLP-1 receptor agonists for kidney transplant recipients
Schmitz, S. H., & Orandi, B. J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf199 · Cited by 9
Bellman, J., Westerterp, K. R., Wouters, L., Johannesson, M., Lundqvist, N., Kullberg, J., Larsson, C. L., Gustafsson, M., Pettersson, S., Fridolfsson, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04143-6 · Cited by 7
Neves, J. S., Lobato, C. B., Leite, A. R., Vale, C., Vasques‐Nóvoa, F., Saraiva, F. A., Leite-Moreira, A. F., Holst, J. J., & Ferreira, J. P. (2025) · Obesity Reviews · doi:10.1111/obr.70043 · Cited by 11
Decoding the hallmarks of GLP-1RA weight-loss super-responders
Venkatakrishnan, A., Murugadoss, K., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag021 · Cited by 7
Brown, J. M., & Huck, D. M. (2025) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2025.102299 · Cited by 6
Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
Abdul‐Hafez, H. A., Awashra, A., Bdir, S., Saife, S., Salah, Q., Barbarawi, M., Swaileh, T., Emara, A., Elgendy, M. S., & Shubietah, A. R. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70152 · Cited by 9
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Medical Management of Obesity: Current Trends and Future Perspectives
Calderón, A., Aguilera-Astudillo, M., Rojas, A. P., Dowlatshahi, S., Kansara, A., Shakil, J., & Patham, B. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1503 · Cited by 8
Microalbuminuria as a Prognostic Marker in Essential Hypertension
Dimitriadis, K. S., Pyrpyris, N., Vakka, A., Iliakis, P., Theofilis, P., Tatakis, F., Beneki, E., Pitsiori, D., Tsioufis, P., Aznaouridis, K. A., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673348953250310044927 · Cited by 11
Lieberman, R. A., Korona-Bailey, J., Banaag, A. L., Fuhrman, B. J., Corrado, R., & Koehlmoos, T. P. (2025) · Military Medicine · doi:10.1093/milmed/usaf522 · Cited by 9
Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments
Pryke, L. A., Koethe, J. R., & Bailin, S. S. (2026) · Current HIV/AIDS Reports · doi:10.1007/s11904-026-00776-1 · Cited by 13
“In addition, the SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% [81] and major kidney disease events by 22% [82].”
Semaglutide and Cardiovascular Outcomes
Campbell, L. A., Jenkins, A. V., & Jackson, C. D. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2400414 · Cited by 6
Health policy for universal, sustainable and equitable kidney care
Silvariño, R., & Solá, L. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00811-7 · Cited by 6
Kotit, S., & Sous, M. (2024) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2024.26 · Cited by 10
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Ahmed, E. O., Gasmallah, S. I., Jalal, M., Mgbechidinma, C. L., & Ahmed, W. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100699 · Cited by 11
Zhang, J., Li, S., Cheng, X., Tan, X. W., Shi, Y., Su, G., Huang, Y., Zhang, Y., Xue, R., Li, J., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052225 · Cited by 6
Kim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Cartwright, B. M. G., Baker, C., Gluckman, T. J., Stucky, N. L., & Emanuel, E. J. (2024) · medRxiv · doi:10.1101/2024.07.26.24311058 · Cited by 5
Ruel, M., Sandner, S. E., Ponnambalam, M., Brown, C., Gaudino, M. F. L., Sun, L. Y., Verma, S., & Poirier, P. (2026) · Circulation · doi:10.1161/cir.0000000000001434 · Cited by 11
EndoBridge 2023: highlights and pearls
Yıldız, B. O., Boguszewski, C. L., Boguszewski, M. C. D. S., Busetto, L., Celik, O., Fuleihan, G. E., Goulis, D. G., Hammer, G. D., Haymart, M. R., Kaltsas, G., et al. (2024) · HORMONES · doi:10.1007/s42000-024-00549-8 · Cited by 5
Research Progress on the Association Between GLP-1 Receptor Agonists and Cardiomyopathy
Yang, X., & Li, X. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm37180 · Cited by 6
Milder, T. Y., Lin, J., Pearson, S., Greenfield, J. R., Day, R. O., STOCKER, S. L., Neuen, B. L., Falster, M. O., & Costa, J. D. O. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16231 · Cited by 5
Obesity Management for Patients with Coronary Artery Disease and Heart Failure
Syed, A. A., Adam, S., Miller, C., & Alkhaffaf, B. H. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.12.006 · Cited by 6
Campain, J., Wakeham, D. J., Dias, K. A., MacNamara, J. P., Samels, M. R., Howden, E. J., Carrick‐Ranson, G., Hieda, M., Levine, B. D., Sarma, S., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70037 · Cited by 8
Rethinking the label anti-obesity medication
Flint, S. W. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00071-8 · Cited by 6
Metoyer, G. T., Whiteson, H. Z., Chen, Y., Li, Y., Gao, C., Menon, G., Bae, S., Lentine, K. L., Segev, D. L., McAdams‐DeMarco, M., et al. (2025) · Clinical Transplantation · doi:10.1111/ctr.70354 · Cited by 7
Conde, A. C., Martínez, J. J. G., Teruel, J. L., Lorite, N. M., Marcos, M. C., Freixa‐Pamias, R., Obaya, J. C., Hermida, Á. B. Á., Ruíz, R. C., Olmo, R. F., et al. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.04.003 · Cited by 9
Muralikrishnan, A. S., Biasin, V., Zabini, D., & Osto, E. (2025) · Acta Physiologica · doi:10.1111/apha.70091 · Cited by 5
Jackson, S. E., Brown, J., Llewellyn, C. H., Mytton, O. T., & Shahab, L. (2025) · medRxiv · doi:10.1101/2025.06.06.25329114 · Cited by 5
The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders
Cosentino, F., Cannon, C. P., & Marx, N. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae112 · Cited by 6
Coronary inflammation: Identification, clinical impact and possible therapeutical solutions
Prati, F., Biccirè, F. G., Mallus, M. T., Mastroianni, F., Gatto, L., Ferrari, M., & Arbustini, E. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134229 · Cited by 6
Subepicardial adipose tissue as a modulator of arrhythmias
Pyman, E., Ernault, A. C., Patel, K. H. K., Ng, F. S., & Coronel, R. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.10.023 · Cited by 5
Lübker, C., Bhavsar, J., Duque do Vale, R., Emerson, S. S., Nørtoft, E., Plutzky, J., Roberts, G., Tarp, J. M., & Lincoff, A. M. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03176-w · Cited by 5
Self-citationLin, C., Chen, J., Meyerowitz‐Katz, G., Huang, Y., & Su, P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16191 · Cited by 5
Hermel, M. H., Minhas, A. M. K., Hinkamp, C. A., Inam, M., Murthy, N., Waldman, C., Chai, Z., Junaid, V., Khoja, A., Sheikh, S., et al. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01276-0 · Cited by 6
Kushner, R. F., Johansen, O. E., Araujo Torres, K., Phan, T.-M., & Marczewska, A. (2025) · Obesities · doi:10.3390/obesities5020029 · Cited by 5
“The percentage of patients experiencing pancreatitis was ≤ 2% across all studies that recorded this AE (22 publications) [11– 14, recorded this AE (22 publications) [11–14,36,40,47,52,62,63,73,77,78,80,81,84,85,89,91,93,94 36 , 40,”
InfluentialSelf-citationKan, R., Wang, S., Meng, X., Guo, Y., Li, D., & Yu, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01995-z · Cited by 7
The evolving burden of obesity in the US: a novel population-level system dynamics approach
McEwan, P. C., Faurby, M. D., Lübker, C., Padgett, T., & Toliver, J. C. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2554518 · Cited by 9
Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis
Stefanou, M., Tentolouris, A., Panagiotopoulos, E., Theodorou, A., Mengel, A., Athanasaki, A., Lambadiari, V., Peppa, Μ., Papadopoulou, Μ., Παρασκευάς, Γ. Π., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109271 · Cited by 6
Ferrari, R., Gowdak, L. H. W., Padilla, F., Quek, D. K., Ray, S., Rosano, G. M. C., Indolfi, C., & Filardi, P. P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041161 · Cited by 11
The Liraglutide Effects in Atrial Fibrillation (LEAF) Study
Goldberger, J. J., Mitrani, R. D., Fishman, J. E., Zaatari, G., Lowery, M. H., Baez-Garcia, C., Aguilar, V., Blandon, C., Hurwitz, B. E., Velasquez, A. H., et al. (2026) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2026.03.026 · Cited by 15
Webb, G. M., Sauter, K. A. D., Takahashi, D. L., Kirigiti, M. A., Bader, L., Lindsley, S. R., Blomenkamp, H., Zaro, C., Shallman, M., McGuire, C. M., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.181968 · Cited by 7
Evolution of multidisciplinary obesity treatments: past, present, and future role of nutrition
Heymsfield, S. B., Atherton, P. J., Christensen, S. M., Tewksbury, C. M., Velazquez, A., Walter, J., & Blaak, E. E. (2025) · Obesity · doi:10.1002/oby.24340 · Cited by 7
Role of hypothalamus function in metabolic diseases and its potential mechanisms
Zhang, X., Yang, J., Li, Y., Li, Y., & Li, G. (2025) · PeerJ · doi:10.7717/peerj.19532 · Cited by 11
Hargovan, S., Hunt, N., Kostakis, H., & Chow, C. K. (2025) · Internal Medicine Journal · doi:10.1111/imj.70160 · Cited by 7
Dong, H., Chang, L., Tian, T., Shi, R., Yu, K., Wang, C., Liu, Z., Jin, Q., Wang, J., He, T., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1724965 · Cited by 9
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
